CGON Relative Valuation
CGON's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CGON is overvalued; if below, it's undervalued.
Historical Valuation
CG Oncology Inc (CGON) is now in the Overvalued zone, suggesting that its current forward PS ratio of 5999.01 is considered Overvalued compared with the five-year average of -19.23. The fair price of CG Oncology Inc (CGON) is between 8.29 to 17.58 according to relative valuation methord. Compared to the current price of 26.90 USD , CG Oncology Inc is Overvalued By 53.06%.
Relative Value
Fair Zone
8.29-17.58
Current Price：26.90
53.06%
Overvalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
2.91
P/B
Median3y
3.00
Median5y
3.00
-4.01
FCF Yield
Median3y
-3.09
Median5y
-3.09
Competitors Valuation Multiple
The average P/S ratio for CGON's competitors is 1217.16, providing a benchmark for relative valuation. CG Oncology Inc Corp (CGON) exhibits a P/S ratio of 5999.01, which is 392.87% above the industry average. Given its robust revenue growth of -90.17%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is CG Oncology Inc (CGON) currently overvalued or undervalued?
What is CG Oncology Inc (CGON) fair value?
How does CGON's valuation metrics compare to the industry average?
What is the current P/B ratio for CG Oncology Inc (CGON) as of Jul 08 2025?
What is the current FCF Yield for CG Oncology Inc (CGON) as of Jul 08 2025?
What is the current Forward P/E ratio for CG Oncology Inc (CGON) as of Jul 08 2025?